Production (Stage)
AnaptysBio, Inc.
ANAB
$20.44
-$0.30-1.45%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 111.87M | 91.28M | 57.17M | 30.47M | 22.96M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 111.87M | 91.28M | 57.17M | 30.47M | 22.96M |
| Cost of Revenue | 167.98M | 163.84M | 154.78M | 143.44M | 134.37M |
| Gross Profit | -56.11M | -72.56M | -97.60M | -112.97M | -111.41M |
| SG&A Expenses | 44.18M | 42.39M | 42.47M | 42.08M | 43.47M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 212.16M | 206.23M | 197.25M | 185.52M | 177.83M |
| Operating Income | -100.29M | -114.95M | -140.08M | -155.05M | -154.87M |
| Income Before Tax | -140.58M | -145.23M | -165.65M | -170.11M | -163.30M |
| Income Tax Expenses | 47.00K | 3.00K | 5.00K | 5.00K | -4.00K |
| Earnings from Continuing Operations | -140.62 | -145.23 | -165.66 | -170.12 | -163.30 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -140.62M | -145.23M | -165.66M | -170.12M | -163.30M |
| EBIT | -100.29M | -114.95M | -140.08M | -155.05M | -154.87M |
| EBITDA | -99.70M | -114.34M | -139.45M | -154.41M | -154.22M |
| EPS Basic | -4.84 | -5.20 | -6.07 | -6.34 | -6.13 |
| Normalized Basic EPS | -3.02 | -3.25 | -3.62 | -3.79 | -3.66 |
| EPS Diluted | -4.84 | -5.20 | -6.07 | -6.34 | -6.13 |
| Normalized Diluted EPS | -3.02 | -3.25 | -3.62 | -3.79 | -3.66 |
| Average Basic Shares Outstanding | 117.34M | 113.50M | 109.64M | 107.29M | 106.56M |
| Average Diluted Shares Outstanding | 117.34M | 113.50M | 109.64M | 107.29M | 106.56M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |